What is a key consideration when using prokinetic medications?

What is a key consideration when using prokinetic medications?

• A. Increased risk of extrapyramidal symptoms and tardive dyskinesia
• B. No adverse effects
• C. Hypotension risk only
• D. Hepatotoxicity risk only

Answer: (A)

Prokinetic medications often work by blocking dopamine D2 receptors to boost gut motility, but those same receptors are in the brain's movement centers. That CNS dopamine blockade can produce extrapyramidal symptoms—like dystonia, parkinsonian features, or akathisia—and, with long-term use, tardive dyskinesia. Because of these movement-related risks, EPS and tardive dyskinesia are the major safety considerations when using these drugs, especially with prolonged therapy or in older patients. Other adverse effects can occur, but they don’t outweigh this key CNS risk. If movement symptoms appear, clinicians typically adjust the dose or change the therapy to avoid this likelihood.

Prokinetic medications often work by blocking dopamine D2 receptors to boost gut motility, but those same receptors are in the brain's movement centers. That CNS dopamine blockade can produce extrapyramidal symptoms—like dystonia, parkinsonian features, or akathisia—and, with long-term use, tardive dyskinesia. Because of these movement-related risks, EPS and tardive dyskinesia are the major safety considerations when using these drugs, especially with prolonged therapy or in older patients. Other adverse effects can occur, but they don’t outweigh this key CNS risk. If movement symptoms appear, clinicians typically adjust the dose or change the therapy to avoid this likelihood.